In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, tolerability, dosage and administration, and place in therapy of dabigatran etexilate are reviewed. Summary. Dabigatran is a ...

Dabigatran also had similar rates of major bleeding and intracranial hemorrhage compared with aspirin (risk differences, 0.5 [95 percent confidence interval, −2.1 to 19.6] and 0.0 [95 percent ...

Am J Health Syst Pharm. 2011;68(16):1506-1519. b These values are mean population values based on data from dabigatran doses ranging from 10 to 400 mg given as single and multiple doses.